The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S.

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Using integrated lab, claims, and EMR data, the manufacturer can pull in test results and deploy NLP on the unstructured EMR ...

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

AdvaMed and other healthcare groups have pleaded for the Trump administration to exempt medical devices and critical supplies ...